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Dietary interventionAmyotrophic lateral sclerosis (ALS) is an adult onset, neurodegenerative disease that is characterized by the loss
of upper (corticospinal) and lower motor neurons. ALS is a multifactorial disease whereby a combination of ge-
netic and environmental factors may contribute to disease pathogenesis. While the majority of studies indicate
that the underlying causes for ALS pathology may be due to multiple defects at the cellular level, factors that
have recently been identiﬁed to be associatedwith survival could lead to the development of beneﬁcial interven-
tions. In ALS, a higher pre-morbid bodymass index (BMI) and themaintenance of BMI and nutritional state is as-
sociated with improved outcome. This review will focus on the associations between body composition and
adiposity relative to disease duration and risk, and will discuss current evidence that supports the beneﬁts of im-
proving energy balance, and the maintenance of body mass through nutritional intervention in ALS.
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1.1. ALS — An aggressive multifactorial disease
Amyotrophic lateral sclerosis (ALS) is an aggressive neurodegenera-
tive disease that is characterized by the concurrent degeneration of
upper and lower motor neurons, and associated networks. This results
in progressive paralysis and eventual death usually from respiratory
failure [1,2]. ALS can be sporadic (90–95%) or familial (5–10%). The clin-
ical presentation of the disease is indistinguishable between sporadic
and familial patients.
1.2. Cause of ALS
The primary underlying cause for ALS remains to be determined, but
as with all complex diseases, is likely to be due to a combination of ge-
netic and environmental factors. Genes that are causative in ALS have
been identiﬁed and include copper–zinc superoxide dismutase 1
(SOD1) [3,4], ubiquitin [5], optineurin [6,7], fused in sarcoma protein
(FUS) [8–12], TAR DNA binding protein of 43-kDa (TDP-43) [13–15],
and C9ORF72 [16,17]. The processes that underlie disease and lead to
cell death include abnormal function and/or pathological aggregation
of SOD 1 [18], FUS, TDP-43, and ubiquitin, excitotoxicity [19–22], mito-
chondrial dysfunction [23,24], non-cell autonomous death [25–29], and
altered metabolic homeostasis [30–34].
While studies indicate that the underlying causes for ALS pathology
may lie at the cellular level, identiﬁcation of modiﬁable factors that pre-
dict the course of disease could lead to beneﬁcial interventions. Factors
that have recently been identiﬁed to be associated with survival in ALS
include body mass index (BMI) and nutritional state. In this review we
will discuss associations between body composition and fatness relative
to disease duration and risk, and current evidence that supports the
beneﬁts of improving energy balance and nutritional intervention in
ALS.
2. ALS — Body mass composition and metabolic considerations
2.1. Body mass index and prognosis in ALS
Weight loss in ALS is universal and is due to loss of muscle mass and
a reduction in body fat mass [35], measured as body mass index (BMI,
deﬁned as weight in kilograms divided by height squared in meters)
[36]. Recent assessment of the relationship between BMI and disease
progression in ALS found that patients with a BMI between 30 to 35
had a better survival outcome than those with a BMI below 30, or
above 35 [37]. A faster rate of reduction in BMI was also been found to
predict shorter length of survival in ALS patients [38]. Most interesting-
ly, recent studies also suggest that higher pre-morbid BMI not only pre-
dicts a better result on the ALS Functional Rating Scale (ALSFRS-R) [39],
but that increased BMI in earlier life is associated with lower incidence
of ALS [40] and decreased risk of ALS mortality [41]. Although these
studies suggest that increased body mass (and presumably fatness) in
ALS may be protective, they do not entirely conﬁrm that a very high
BMI is beneﬁcial in ALS. In fact, the association of BMI with survival in
ALS is denoted by a “U” shaped curve, wherein low and high BMIs are
detrimental to survival duration [37]. With respect to the detrimental
effects of high BMI in ALS, it could be expected that co-morbidities (in-
cluding cardiovascular disease and type II diabetes) associated with
being obese [42] would be the cause of reduced survival. However,
Paganoni and colleagues found that while cardiovascular disease oc-
curred at a higher incidence in an ALS cohort with a BMI of N35 (com-
pared to patients with a lower BMI), the increased mortality in this
cohort was not directly related to cardiovascular events [37]. Moreover,
ALS patients with type II diabetes appear to have later disease onset
[43,44]. Thus, factors contributing to poor survival in patients with a
BMI above 35 are yet to be elucidated, but do not appear to be due tocomplications arising from cardiovascular disease or diabetes. Similarly,
little is known regarding the factors associated with improved survival
in ALS patients with a BMI of 30 to 35. Common theories include provi-
sion of higher baseline energy reserves needed tomitigate increased en-
ergy requirements associated with ALS, and altered lipid metabolism.
2.2. Evidence that adiposity and lipids inﬂuence disease progression in ALS
Above we presented evidence demonstrating an association be-
tween BMI and the risk of developing ALS, disease outcome and disease
progression. We now discuss the role of adiposity and lipids in ALS.
Whilst BMI is inﬂuenced by fat mass, BMI is determined by all com-
ponents of the body including lean muscle mass. Accordingly, fat mass
may largely determine BMI in obese individuals, whilst muscle mass
may greatly contribute to BMI in a lean individual. In this regard, a de-
crease in BMI in ALSmay not be due solely to a loss in fatmass, but rath-
er rapid weight loss and the resulting reduction in BMI may result from
muscle atrophy due to denervation [45]. Loss of motor function
resulting in difﬁculty in feeding due to upper limb weakness, and a re-
duction in food intake due to dysphagia in ALS [46]may result inmalnu-
trition and contribute to this reduction in muscle mass (proteolysis).
Consequently, measures of BMI may not speciﬁcally address the role
of fat mass in ALS survival, and thus should be treated accordingly.
Detailed measures of adiposity and survival in ALS are limited, how-
ever existing observationsprovide some insights to delineate the poten-
tial beneﬁcial role of fat mass and ALS survival. Assessment of ALS
patients within the European Prospective Investigation into Cancer
and Nutrition (EPIC) cohort of individuals revealed that an increase in
pre-morbid body fat mass was associated with decreased risk of ALS
mortality [41].While limited by the extrapolation of fatness through as-
sessment of BMI, this study included comparisons between ALS survival
andwaist to hip ratio (WHR). This is important, asWHR is considered to
be a predictor of abdominal adiposity [47]. While demonstrating a non-
signiﬁcant trend showing reduced risk of ALS relative to an increase in
WHR, the data highlighted a potential divergence in risk between
males and females. In men, no relationship betweenWHR and ALS sur-
vival was observed, while a signiﬁcant reduction in riskwas observed in
women relative to an increase inWHR. Given that the deposition of ad-
ipose in the waist and hip varies between males and females [48], it
would seem relevant that future studies would also consider gender
speciﬁc analysis of waist and hip circumference with respect to the
risk of developing ALS.
To our knowledge, Lindauer et al. (2013) conducted the only com-
prehensive study that speciﬁcally assesses the relationship between ad-
ipose mass and ALS survival. Lindauer and colleagues used MRI-based
methodologies to quantify fat distribution, and presented observations
relative to visceral (fat located around organs) and subcutaneous fat
mass (fat underlying the skin). While demonstrating a trend for im-
proved duration of survival of ALS patients relative to increased total
and visceral fat mass, a signiﬁcant relationship was only observed rela-
tive to subcutaneous fat mass. Importantly, these observations were
speciﬁc to male patients, suggesting a potential gender speciﬁc differ-
ence in the role of adipose mass in the prediction of survival in ALS.
Given that adipose tissue represents the primary store of energy, and
there are known alterations in energy demands associated with ALS
(see below), onemay conclude that altered fatmass infers a survival ad-
vantage through the sustained provision of energy. Of course, this as-
sumes mechanisms that mediate the movement of energy out of
storage, and that facilitate the use of fat as energy remain intact.
While there is good evidence that higher BMI is a predictor of ALS
risk and survival, other studies have assessed the levels of lipids in circu-
lation in relation to the prognosis of ALS. Although some studies show
prolonged survival in patients with elevated levels of total cholesterol,
low-density lipoprotein (LDL), LDL/high-density lipoprotein (HDL)
ratio, or triglycerides [49,50], conﬂicting observations suggest that
total cholesterol, triglycerides, LDL, HDL and the LDL/HDL ratio between
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been found that cholesterol and LDL are unchanged in ALS patients
throughout the course of disease [37]. Thus, whether dyslipidemia ex-
ists in ALS, andwhether dyslipidemia is related to or able to predict sur-
vival in ALS remains to be conﬁrmed. Given that hyperlipidemiamay be
beneﬁcial, and as lipid-lowering statinsmay cause neuromuscular dam-
age and upper motor neuron lesions or an ALS-like syndrome [51], it
would seem prudent to be cautious about the treatment of hyperlipid-
emia, especially with statins, in ALS patients.
2.3. Hypermetabolism in ALS
Hypermetabolism, deﬁned as a signiﬁcant increase inmetabolic rate
at rest [52], is observed in ALS patients at the whole body level
[30,32–34] andwithin the brain [31]. Consistent with hypermetabolism
and negative energy balance, reduced total body weight is seen in ALS
[53,54]. In part, thismay underlie the close association between survival
and the aggregation of adipose stores. The mechanisms that underlie
the development of hypermetabolism in ALS remain unknown. It has
been proposed that mitochondrial defects inherent to ALS could drive
the hypermetabolic phenotype [23,24,55]. Reduced mitochondrial ca-
pacity, leading to increased reactive oxygen species may alter pH [56],
which may in turn contribute to metabolic dysfunction [57].
Attempts have been made to further understand hypermetabolism
in ALS. In this regard, efforts to alter systemic metabolism or efforts to
balance energy homeostasis may modify disease outcome. Hyperme-
tabolism inmousemodels of ALS (SODG93A and SODG86R) is demonstrat-
ed by an increase in resting energy expenditure [58,59]. Comprehensive
assessment of the metabolic proﬁle of SODG86R mice at the asymptom-
atic and symptomatic stages of disease reveals depletion of lipid stores,
altered carbohydrate metabolism, and glucose accumulation in skeletal
muscle [58]. Complimentary to this, altered glucose ﬂux and lipid me-
tabolism is observed in SODG93Amice, and there is an increased tenden-
cy for the peripheral clearance of lipids in response to high fat feeding
[57,60]. By compensating for an increase in energy demand through
high fat feeding, Dupuis and colleagues were able to extend mean sur-
vival in SODG86R mice [58]. Taken together, these studies provide com-
pelling evidence to suggest that hypermetabolism in ALS is of skeletal
muscle origin, and that increased energy demandmay partially underlie
the mobilization and eventual depletion of fat mass (and body weight/Fig. 1. Potential implications of increased energy requirements in amyotrophic lateral sclerosis
meostasis is maintainedwithin a healthy range. Energy intake (from dietary sources) is used to
inability tomaintain energy intake results in negative energybalance. Duringnegative energyba
Hypermetabolism in ALS is deﬁned by an increase in energy demand. In ALS, decreased energ
dependence on the use of stored energy. This allows for the continual supply of energy substr
results in a decrease in body mass index. The capacity to sustain energy requirements (from d
hypermetabolic ALS patients.BMI) that is observed in ALS. Considering this, close associations be-
tween adiposity and survival in ALSmay simply be reﬂective of a capac-
ity or tendency to compensate for the hypermetabolic state.
2.3.1. Altered energy supply during periods of negative energy balance in
ALS
In both health and disease, energymetabolism and themaintenance
of body composition are tightly regulated to sustain energy homeostasis
(Fig. 1). During periods of energy surplus (healthy population), endo-
crinemechanisms promote themovement of energy into storage for fu-
ture use. Conversely, during periods of negative energy balance (ALS),
endocrine factors may act to preserve protein (muscle) by promoting
the mobilization and use of fat as the preferential energy substrate.
Prolonged negative energy balance results in a gradual depletion of en-
ergy stores. This is followed by a reduction in circulating blood glucose
levels, while glycogen stores in the liver and muscle are rapidly con-
sumed as an alternative energy substrate [61]. Following the depletion
of glycogen stores, energy demands are met through the use of triglyc-
erides, which are stored in the liver (short-term use) and in adipose tis-
sue (long-term use). The breakdown of triglycerides results in free fatty
acid release. These non-esteriﬁed free fatty acids (NEFAs) are then used
by the liver and by muscle to sustain continued energy supply. Follow-
ing prolonged negative energy balance, NEFAs are converted to ketone
bodies; the energy supply of last resort used by critical organs such as
the brain, heart and kidneys. Prolonged catabolism of triglycerides dur-
ing extended periods of negative energy balance results in a signiﬁcant
loss in body fat mass [62,63]. Given that maintenance of optimal nutri-
tion is central to survival in health and in disease, it comes as no surprise
that numerous intricate systemswork in synergy to sustain energy sup-
ply during periods of negative energy intake. Comprehensive investiga-
tions targeting endocrine components speciﬁcally underlyingmetabolic
responses in ALS patients are yet to be conducted, however attempts to
modify disease progression through altered endocrine function in pre-
clinical models of ALS have been attempted.
Thyroid hormones play an important role in regulating metabolism
[64,65]. Thyroxine (T4) is the main hormone produced by the thyroid
gland and undergoes conversion in tissues to tri-iodothyronine (T3)
[66]. T3 directly regulates mitochondrial uncoupling proteins 1 and 3,
and thus control energy production and thermogenesis [67,68]. Accord-
ingly, reductions in T3 levels results in increased coupling and reduced(ALS). In the healthy population, and under periods of normal energy demand, energy ho-
meet energy demands. Excess energy is shunted into the liver and adipose for storage. An
lance, energy reserves in the liver and adipose are used in order to supply energy demands.
y intake results in decreased storage of energy in the liver and adipose, and an increased
ates to meet energy requirements. Hypermetabolism and negative energy balance in ALS
ietary sources or through release of endogenous stores) may predict survival duration in
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tion in coupling and increased metabolism. Pharmacological induction
of hypothyroidism with methimazole was unable to prolong survival
in SODG93A mice [69]. These observations suggest that the alleviation
of systemic hypermetabolism by targeting T4 does not modify disease
outcome. However, results from this study must be interpreted with
caution, because of the limited number of animals and the lack of infor-
mation to describe improvedmetabolic balance. Serum levels of thyroid
hormones in ALS patients are within a normal range [70,71], and thus it
seems unlikely that altered thyroid function underlies hypermetabo-
lism in ALS. In line with this, thyrotropin-releasing hormone (TRH)
treatment does not represent a viable therapeutic option for ALS pa-
tients [72]. However, these results donot negate the potential therapeu-
tic value of other endocrine regulators of metabolism.
Recent observations demonstrate elevated levels of circulating
growth hormone in SODG93A mice at a time representative of the
onset of disease symptoms [73]. While patients are growth hormone
deﬁcient at the latter stages of disease (as is seen in the SODG93A
mouse [74]), the role and the release of growth hormone relative to dis-
ease progression in patients remain unknown. Of interest, growth hor-
mone is a key anabolic hormone that facilitates the use of fat to
preserve muscle during periods of negative energy balance [75]. Thus,
altered growth hormone release at disease onset in SODG93A mice may
represent an endogenous response to altered metabolic demands, and
may thus drive themobilization of NEFAs tomeet energy requirements.
Given that clinical trials relying on growth hormone treatment demon-
strate no beneﬁcial effects in patients [76,77], the implications of altered
growth hormone release throughout disease progression in ALS re-
mains unknown. Thus, at the time of assessment of the potential bene-
ﬁts of growth hormone treatment in ALS, the physiological actions of
growth hormone had not been assessed in context to its role speciﬁc
to disease progression. More importantly, whether altered growth hor-
mone release exacerbates hypermetabolism requires further assess-
ment. This is important, given that growth hormone and associated
endocrine factors not only mediate energy ﬂux, but also determine the
utilization of energy by organs, including muscle [78–80].
3. Maintaining BMI in ALS: measures that may counteract weight
loss and hypermetabolism in ALS
3.1. Nutrition in ALS
Caloric restriction in healthy individuals (deﬁned as 30% to 60% de-
crease in ad libitum food intake exclusive of malnutrition) increases
lifespan by delaying the onset of age-associated diseases [81–84]. In in-
dividuals with metabolic disorders (e.g. obesity and diabetes mellitus),
calorie restriction improves lifespan by reducing both subcutaneous
and visceral fat mass [85,86]. Given the observed beneﬁts of caloric re-
striction on lifespan in these groups, the beneﬁts of caloric restriction
have been assessed in rodent models of ALS [87–89]. In these models,
caloric restriction provided a transient improvement in motor perfor-
mance. This might be attributed to an increase in nicotinamide adenine
dinucleotide/sirtuin mediated pathways that improve metabolic bal-
ance during caloric restriction [90,91]. However, it is unlikely that
there are prolonged beneﬁts of the activation of these pathways in
ALS since caloric restriction resulted in alarming reductions in body
weight, and an overall reduction in mobility and fore-paw grip endur-
ance. Most strikingly, caloric restriction induced faster onset of clinical
symptoms, and shortened lifespan [87–89]. While the negative impact
of caloric restriction on disease progression in ALS rodents is attributed
to lipid peroxidation, inﬂammation, and apoptosis [89], it is well known
that reduced body weight contributes negatively to ALS [53,92], and
that reduced deposition of subcutaneous fat mass is associated with
poorer ALSFRS-R [93]. Thus, caloric restriction may accelerate disease
progression by aggravating conditions associated with malnutrition in
ALS, thereby exacerbating the decrease in BMI that is seen in ALSpatients throughout the course of disease. Given the prevailing hyper-
metabolic state of ALS patients, coupled with existing energy deﬁcits,
further restrictions in food intake are highly likely to aggravate disease
progression and should be approached with extreme caution. More im-
portantly, these studies demonstrate the value of optimal nutrition and
sustained calorie intake in ALS.
In ALS, malnutrition at the time of diagnosis or during the course of
disease is associatedwith shorter duration of disease [94] and increased
mortality [95]. Consequently, the American Academy of Neurology and
the European Federation of Neurological Societies advocate regular nu-
tritional evaluation in ALS [96,97]. Factors that contribute to impaired
nutrition and weight loss include dysphagia [98–103], loss of appetite
[104], impaired chewing and deﬁcits in tongue muscles [101], muscle
wasting in the hands resulting in impaired capacity to for unassisted
preparation and consumption of food [105], and hypermetabolism
[30,31]. More importantly, the adverse physiological consequences of
hypermetabolism dictate that hypermetabolic individuals need to in-
crease food consumption in order to sustain energy substrates. Howev-
er, ALS patients do not consume enough calories to compensate for
increased energy need [35]. Given the implications of the loss of fat
mass and reduced BMI in ALS disease progression, a number of inter-
ventions have been developed in order to ensure adequate nutrition
inALS. Interventions include changing food consistency and assisted feed-
ing [106], enteral nutrition (eg. percutaneous radiological gastrostomy/
radiologically inserted gastrostomy (PRG/RIG) [107–109] or percutane-
ous endoscopic gastrostomy (PEG)) [54,106,110,111] or, nutritional sup-
plementation with high-calorie diets [112] or nutriceuticals [113,114].
These considerations will be discussed below.
3.2. Percutaneous radiological gastrostomy and percutaneous endoscopic
gastrostomy
Enteral feeding is recommended in ALS patients who losemore than
10% of their baseline body weight, or in those who have reduced respi-
ratory function [97]. Assisted feeding by gastrostomy is also indicated in
ALS patients who have bulbar symptoms, lower dietary intake, fatigue
or anxiety associated with eating, sialorrhea, dehydration, and dyspha-
gia with aspiration [106]. PRG is better tolerated than PEG and has not
been associated with major complications. While PRG reduces aspira-
tion, studies do not indicate a signiﬁcant improvement in survival in pa-
tients using PRG over PEG [107–109,115]. PEG feeding in ALS is not
associatedwithmajor short or long-term complications. Assisted feeding
by PEG has been shown to stabilize or increase patient bodyweight after
use, improve survival, and improve quality of life [110,111,116,117].
However, heterogeneity in the presentation of disease and variable dis-
ease course in ALS is associated with difﬁculties in the identiﬁcation of
patients who have sufﬁcient respiratory function with minimal weight
loss,modest dysphagia, andwho are psychologically prepared for enteral
feeding. Consequently, other means of nutritional management are
considered for maintaining body weight in ALS.
3.3. High caloric diets in ALS
ALS patients are reported to consume 15–16% fewer calories than
recommended [35]. Since inadequate nutrition andweight loss contrib-
ute negatively to disease, it is recommended that ALS patients consume
calories in excess of their calculated daily needs [35,113,118]. Studies
that assess the beneﬁts of high protein or high carbohydrate diets in
ALS are limited. However, a number of studies have suggested that sup-
plementation with high fat diets is associated with reduced risk of ALS
[119–121].Whether improvedoutcomes are associatedwith speciﬁc di-
etary substrates, or simply the provision of excess calories remains to be
determined. Studies assessing the potential therapeutic value of speciﬁc
dietary components, including protein, carbohydrates and fat are
discussed below.
9S.T. Ngo et al. / Journal of the Neurological Sciences 340 (2014) 5–123.3.1. Protein
Few studies have assessed the beneﬁts of a high protein diet on ALS
progression. A study of 6 months of supplementationwith protein (18 g
protein and 275 kcal) in 20 ALS patients reported no signiﬁcant im-
provement on disease progression or alleviation in the loss of muscle
mass [122]. More recently, a study that provided supplementation
with 70%:30% of milk whey proteins:modiﬁed starch in 16 ALS patients
over a 4 month period, reported a small increase in body weight, and a
slight increase in body mass index (BMI) when compared to those pa-
tients who did not receive supplementation. Patients receiving milk
whey protein:modiﬁed starch had stabilization of the ALSFRS-R, whilst
the ALSFRS-R declined throughout the study in patients not receiving
supplementation [123].While suggesting that a dietwith increased pro-
tein content may be favorable in maintaining nutritional state and/or
BMI in ALS, it remains unclear whether this is due to supplementation
with protein or simply due to an increase in caloric consumption.
3.3.2. Carbohydrates
As with high protein diets, limited information exists regarding
the beneﬁt of a high carbohydrate diets in ALS patients. High carbohy-
drate supplementation (0% fat, 89% carbohydrate, and 11% protein;
900 kcal/day) has been assessed in a cohort of 14 ALS patients over a
3-month period. Outcomes demonstrate a stabilization of body weight,
but no improvement in muscle mass or ALSFRS-R [112]. These observa-
tions are hard to interpret, given the small patient cohort, a high drop-
out rate (38%), and high levels of non-compliance. Furthermore,whether
outcomes from this study were due to supplementation with carbo-
hydrates, or an increase in caloric consumption also remains to be
determined. More recent observations provide promising evidence
supporting improved prognosis following intervention with a high-
calorie high-carbohydrate diet [148]. Future trials that include a
larger group of patients are needed to provide more deﬁnitive
information regarding the efﬁcacy of high carbohydrate diets in ALS.
3.3.3. Fat
The possible beneﬁt of high fat diets in ALS is attracting signiﬁcant
interest. In the SODG86R mouse model of ALS, supplementation with
21% butter fat (animal fat) and 0.15% cholesterol (wt/wt) led to an in-
crease in body weight, an increase in retroperitoneal and epididymal
fat pad mass, and an extension in survival from 102.3 ± 1.6 days to
122.5 ± 4.5 days [58]. Likewise, supplementation with 47% animal fat,
38% carbohydrates, and 15% protein (calorie content) in the SODG93A
mouse model was able to increase body weight, and extend survival
from 180 days to between 220 and 270 days [124]. While the mecha-
nisms by which high fat diets improve body weight and survival in
mouse models of ALS remains to be elucidated, excess energy substrate
provided in the form of fat may compensate for the hypermetabolism
[125], and altered lipid metabolism [60] observed in ALS mice. Com-
pared to high protein or high carbohydrate diets, high fat dietsmay pro-
vide an easier way to sustain greater calorie intake (given the higher
energy content of high fat foods).
Dorst and colleagues assessed the effects of high fat diet supplemen-
tation in ALSpatients [112]. In 12ALS patients, dietary interventionwith
a food supplement consisting of 35% fat, 50% carbohydrates, and 15%
protein (900 kcal/day) promoted an increase in body fat and stabili-
zation body weight [112]. However there was no reported improve-
ment in ALSFRS-R and there was no direct comparisons with non-
supplemented participants. Again, whether increased body fat and
maintenance of body weight in this cohort of patients resulted
from dietary supplementation with fat, or is due to an increase in
overall caloric consumption remains to be resolved. Current observa-
tions inmousemodels of ALS, and in ALS patients provide compelling
evidence to support further research that aims to ascertain the po-
tential therapeutic beneﬁts of a high fat diet regimen in ALS. In this
regard, a Phase II clinical trial aimed at assessing the beneﬁt of a high
fat/high calorie diet in ALS patients has recently been completed(Clinicaltrials.gov ID NCT00983983). In the same vein, given the impor-
tance of maintaining nutrition and appetite in ALS, a Phase II/III clinical
trial that aims to investigate the effectiveness of olanzapine in promot-
ing appetite and weight gain and/or stabilization in ALS has also been
developed (Clinicaltrials.gov IDNCT00876772). Results from these clin-
ical trials are pending.
3.3.4. Alternate approaches: ketogenic diets andmedium chain triglycerides
3.3.4.1. Ketogenic diet. The ketogenic diet is a calorie-restricted, high fat,
low protein, low carbohydrate diet. Because mitochondrial dysfunction
is thought to be involved in ALS pathogenesis [23,24,126], ketogenic
diets may be beneﬁcial as they may serve to promote the production
of ketones from the liver, which in turn may act to improve mitochon-
drial metabolism and biogenesis [127,128]. Though no improvement
in survival has been observed in SODG93A mice supplemented with a
ketogenic diet (caloric composition: 60% fat, 20% carbohydrate, 20%
protein/caloric composition), an improvement in motor performance,
increased body weight, and reduced motor neuron death was observed
when compared to SODG93Amice on a control diet (caloric composition:
10% fat, 70% carbohydrate, 20% protein/calorie consumption) [129]. Al-
though compliance with the strict and unpalatable ketogenic diets is
difﬁcult [130–132], results in ALS mouse models are fairly promising.
Accordingly, a clinical trial (NCT01016522) that aims to test the safety
and tolerability of the ketogenic diet (80% fat, 3% carbohydrate, 17% pro-
tein) in ALS was initiated in 2009. To our knowledge, the outcomes of
this trial have not been revealed.
3.3.4.2. Medium chain triglycerides. Oral medium chain triglycerides are
highly ketogenic [133,134]. The effects of the medium chain triglycer-
ide, caprylic triglyceride (octanoate), on disease outcome have been
assessed in SODG93A mice [135]. While dietary supplementation with
10% caprylic triglyceride in SODG93A mice resulted in improved motor
performance and protection against motor neuron death, no improve-
ment in survival outcome was apparent [135]. Overall, a ketogenic
diet and octanoate may improve motor performance and rescue
motor neurons [129,135], although they seem to provide minimal ben-
eﬁt in modifying the duration of disease. Whether supplementation
with higher amounts of medium chain triglycerides is advantageous in
ALS remains to be determined.
3.4. Nutriceuticals/dietary supplements in ALS
Nutriceuticals [113,114] are deﬁned as “a food (or part of a food) that
provides medical or health beneﬁts, including the prevention and/or treat-
ment of a disease” [136]. The use of nutriceuticals is common in ALS pa-
tients, with 54.5% of ALS patients reporting regular intake of dietary
supplements, and up to 44.8% of these patients reporting the consump-
tion of a cocktail of multiple supplements [53]. Nutriceuticals and die-
tary supplements are popular amongst ALS patients as it is suggested
that theymay provide beneﬁts by targeting themechanisms that under-
lie disease pathophysiology including oxidative stress, glutamate
excitotoxity, mitochondrial dysfunction, inﬂammation, and protein
and RNA toxicity. Commonly used supplements include vitamin E, vita-
min B6 and B12, folate, green tea extract, coenzyme Q10, zinc, melato-
nin, and creatine, amongst many others. The rationale underlying the
use of supplements, and studies that assess their beneﬁts in ALS has
been reviewed previously [106,114]. Brieﬂy, few observations exist to
support the beneﬁts of these substances in the pathogenesis of ALS,
however some promising observations exist regarding the potential
therapeutic beneﬁts of Vitamin E [121,137,138]. It is of critical impor-
tance that beneﬁts and potential side effects of existing nutriceuticals
and dietary supplements in ALS are assessed, given their widespread
use bypatients. Second to this, it is critical thatwe consider the potential
beneﬁts of nutriceuticals shown to be effective in in vitro and in vivo
models of ALS.
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plants [139]. It has been described to have a number of health promot-
ing beneﬁts in cancer [140] and cardiovascular disease [141]. The pro-
tective effects of resveratrol have been attributed to its activation of
sirtuin 1 [142]. In 2011, two independent studies demonstrated an at-
tenuation of neuronal death by resveratrol; motor neuron-like cultures
harboring themutant human SODG93A displayed increased viability and
increased energy production [143], and rat cortical motoneurons were
protected from calcium-mediated death thatwas driven byALS cerebral
spinal ﬂuid [144]. Most recently, dietary supplementationwith resvera-
trol in SODG93A mice prior to, and after the onset of symptoms resulted
in an attenuation of motor neuron death, improvedmotor function, and
an extension in survival [145]. While this was attributed to an increase
in the expression of sirtuin 1 and improved metabolic capacity, the low
oral bioavailability of resveratrol [146]may necessitate high oral dosage
to achieve similar beneﬁcial effects in humans.We are not aware of any
current clinical trials that are assessing the potential beneﬁts and side
effects of resveratrol in ALS.
4. Conclusion
There is increasing evidence to suggest that higher pre-morbid BMI,
maintenance of BMI, dyslipidemia, and improved nutrition is associated
with improved outcome in ALS.While current data assessing the impact
of dyslipidemia on survival outcome in ALS is contradictory, the beneﬁt
of increased pre-morbid BMI, a stably maintained BMI, and a high-fat
diet regimen in ALS is more consistent. Despite these observations, the
mechanisms by which elevated/maintained BMI and improved high ca-
loric intake improve the prognosis in ALS remain to be determined. One
plausible mechanism may be the provision of increased energy sub-
strates to account for increased energy needs in ALS [147]. Indeed,
higher BMI may be associated with increased levels of baseline energy
stores, or increased readily available energy substrates associated with
food intake. This is consistent with observations that declining BMI
throughout the course of disease, which may be resultant of hyperme-
tabolism and negative energy balance, is associatedwith shorter surviv-
al, and that the preservation of adequate nutrition is associated with
maintenance of body weight, better survival outcome and improved
quality of life. Future work that dissects out the mechanisms by which
BMI or nutritional/dietary management contribute to better survival
in ALS will provide essential knowledge to allow successful translation
of adoptive practices into the clinic. This is of particular importance,
given potential beneﬁts, the relatively low cost to beneﬁt ratio, and
the relative ease through which improved dietary habits may be
adopted. Ultimately, the improvement of metabolic balance in patients,
and potentially the improved progression of disease outcome, depend
on rigorous assessment of the mechanisms through which dietary sup-
plementationmaymodify the course of disease, and the identiﬁcation of
critical dietary factors essential to survival in ALS.
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